Monday, February 28, 2011

EXEL: The Next Killer Stock?

The only reason I won't put EXEL on my "Next Killer Stock" list (which currently comprises 6 stocks) is because the company is still in developmental stage and is unprofitable, but it has huge future potential.

Here is a video testimonial of drug XL184, Exelixis' main drug.

No comments:

Post a Comment